1 2 2	A Novel Digital Twin Strategy to Examine the Implications of Randomized Clinical Trials for Real-World Populations
4	Phyllis M. Thangaraj ^{1*} , Sumukh Vasisht Shankar ^{1*} , Sicong Huang ³ , Girish N. Nadkarni ^{4,5} , Bobak
5	J. Mortazavi ³ , Evangelos K. Oikonomou ¹ , and Rohan Khera ^{1,2,6,7}
6	
7	¹ Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of
8	Medicine, New Haven, CT, USA
9	² Section of Health Informatics, Department of Biostatistics, Yale School of Public Health,
10	New Haven, CT
11	³ Department of Computer Science and Engineering, Texas A&M University, College Station,
12	TX
13	⁴ The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at
14	Mount Sinai, New York, NY, USA
15	⁵ The Division of Data Driven and Digital Medicine, Department of Medicine, Icahn School of
16	Medicine at Mount Sinai, New York, NY, USA
17	⁶ Section of Biomedical Informatics and Data Science, Yale School of Medicine, New Haven,
18	CT
19	⁷ Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT,
20	USA
21	*Contributed Equally
22 23 24 25 26 27 28	Manuscript Type: Article Words: Abstract: 279 Text: 3824
29	*Address for correspondence:
30	Rohan Khera, MD, MS
31	195 Church St, 6th Floor, New Haven, CT 06510
32 33	203-764-5885; rohan.khera@yale.edu; @rohan_khera

34 ABSTRACT

35

36 Randomized clinical trials (RCTs) are essential to guide medical practice; however, their

- 37 generalizability to a given population is often uncertain. We developed a statistically informed
- 38 Generative Adversarial Network (GAN) model, RCT-Twin-GAN, that leverages relationships
- 39 between covariates and outcomes and generates a digital twin of an RCT (RCT-Twin)
- 40 conditioned on covariate distributions from a second patient population. We used RCT-Twin-
- 41 GAN to reproduce treatment effect outcomes of the Systolic Blood Pressure Intervention Trial
- 42 (SPRINT) and the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood
- 43 Pressure Trial, which tested the same intervention but found different treatment effects. To
- 44 demonstrate treatment effect estimates of each RCT conditioned on the other RCT's patient
- 45 population, we evaluated the cardiovascular event-free survival of SPRINT digital twins
- 46 conditioned on the ACCORD cohort and vice versa (ACCORD twins conditioned on SPRINT).
- 47 The conditioned digital twins were balanced across intervention and control arms (mean absolute
- 48 standardized mean difference (MASMD) of covariates between treatment arms 0.019 (SD
- 49 0.018), and the conditioned covariates of the SPRINT-Twin on ACCORD were more similar to
- 50 ACCORD than SPRINT (MASMD 0.0082 SD 0.016 vs. 0.46 SD 0.20). Notably, across
- 51 iterations, SPRINT conditioned ACCORD-Twin datasets reproduced the overall non-significant
- 52 effect size seen in ACCORD (5-year cardiovascular outcome hazard ratio (95% confidence
- 53 interval) of 0.88 (0.73-1.06) in ACCORD vs. median 0.87 (0.68-1.13) in the SPRINT
- 54 conditioned ACCORD-Twin), while the ACCORD conditioned SPRINT-Twins reproduced the
- 55 significant effect size seen in SPRINT (0.75 (0.64-0.89) vs. median 0.79 (0.72-0.86)) in the
- 56 ACCORD conditioned SPRINT-Twin). Finally, we demonstrate the translation of this approach
- 57 to real-world populations by conditioning the trials on an electronic health record population.
- 58 Therefore, RCT-Twin-GAN simulates the direct translation of RCT-derived treatment effects
- 59 across various patient populations.

60 INTRODUCTION

Randomized clinical trials (RCTs) generate evidence that defines optimal clinical practices, but their generalizability to real-world patient populations is often challenging to quantify.^{1,2} This is a concern because RCTs often have underrepresentation from several demographic and clinical subpopulations^{3–7} and varying treatment effects among individuals with certain characteristics.^{8–} ¹⁰ These considerations are critical to translating information from RCTs to real-world patient populations,^{11,12} but no strategies exist to evaluate how they may affect the applicability to patients in these settings.

68 Variation across RCTs testing similar interventions with discrepant treatment effects is a key issue for the generalizability of interventions tested in RCTs.^{13–19} For example, the Systolic 69 70 Blood Pressure Intervention Trial (SPRINT) was a treatment intervention RCT that showed improved cardiovascular outcomes with intensive blood pressure control.¹³ In contrast, the 71 72 Action to Control Cardiovascular Risk in Diabetes Blood Pressure (ACCORD) trial did not find improved cardiovascular outcomes with the same intervention.¹⁴ Among the explanations posited 73 74 for these discrepant findings include differences in population composition and event rates.^{20–23} 75 Despite experimental evidence from two trials, there is no quantitative strategy to evaluate these 76 assertions explicitly. Therefore, while it is critical to evaluate whether the effects observed in an 77 RCT population generalize to a second population – either a planned second RCT or a general 78 population of patients with the condition – the challenge remains to examine these effects in the 79 context of the complex differences across multiple population characteristics.

Digital twins of RCTs introduce a strategy to create a synthetic representation of a
clinical trial updated by attributes of a second population. Specifically, trial-level digital twin
synthesis through deep generative models such as Generative Adversarial Networks (GANs) can

83	integrate multiple covariates from a patient cohort by constructing a digital twin with covariate
84	values sampled from the second cohort while retaining relationships and correlations between
85	variables within the original RCT. While GANs have been utilized to estimate individual
86	treatment effects, their potential for evidence translation across patient populations has not been
87	explored. ^{24–27} Conditional GANs (CGAN) enable the generation of synthetic datasets that
88	condition a model with covariates from a second population distribution. ^{28,29} We hypothesize that
89	applying this model to an RCT conditioned on a second population will estimate the treatment
90	effects of the original RCT in the new patient population.
91	We present RCT-Twin-GAN, a generative framework that combines clinical knowledge
92	and the statistically informed architecture to create a digital twin of an RCT conditioned on the
93	characteristics of a second patient population to assess for the generalizability of the treatment
94	effect (Figure 1, Figure 2). To demonstrate the ability of the digital twin to replicate treatment
95	effects in the conditioning population, we first compared two RCTs, SPRINT and ACCORD,
96	with similar interventions but disparate treatment effects on cardiovascular outcomes. We created
97	a digital twin of each of the 2 RCTs conditioned on covariate distributions of the other and
98	evaluated whether the RCT-Twins reproduced the treatment effect of the conditioning cohort.
99	Finally, we describe the cardiovascular outcomes of SPRINT and ACCORD digital twins
100	conditioned on characteristics of patients in the electronic health record (EHR), introducing the
101	role of RCT-Twins in estimating RCT treatment effects in real-world populations.
102	
103	RESULTS

104 Study Populations

105 The study developed digital twins of two RCTs. The first RCT, SPRINT, was a treatment 106 intervention study to test whether intensive blood pressure control (goal systolic blood pressure 107 less than 120 mmHg) versus standard care (goal systolic blood pressure less than 140 mmHg) 108 reduced major cardiovascular events. The trial consisted of 9361 participants (median age 67 (61 109 to 76 (25-75% IQR, and 3332 (36%) women). The patients in SPRINT were followed for a 110 median of 3.26 years for the first occurrence of any of the primary composite outcome of 111 myocardial infarction, acute coronary syndrome, stroke, heart failure, or death from 112 cardiovascular cause. 113 Our study built a SPRINT digital twin with a population representation of another RCT 114 with the same intervention, the ACCORD trial, a double factorial RCT of participants with type 115 2 diabetes mellitus and cardiovascular disease. We specifically leveraged the blood pressure 116 management component of the ACCORD trial, wherein half of the participants were randomized 117 to intensive versus standard care blood pressure control, with the same treatment goals as those 118 in the SPRINT trial. ACCORD consisted of 4733 participants (median age 62, IQR, 58-67, and 119 2258 [48%] women). ACCORD median follow-up time was 4.7 years for the primary composite 120 outcome of myocardial infarction, stroke, or death from cardiovascular cause. 121 We also incorporated two cohorts from the Yale New Haven Hospital Health System 122 Electronic Health Record (EHR), a large healthcare system including several hospitals with 123 diverse racial and socioeconomic demographics across Connecticut and Rhode Island. Two sets 124 of patients with hypertension, one without (N=22,132) and the other with diabetes (N=8,840)125 were identified to broadly represent populations included in SPRINT and ACCORD, 126 respectively, to estimate the treatment effects found in the two RCTs on corresponding real-127 world patient populations. The final cohorts included 3,130 patients in the SPRINT EHR cohort

- and 2,731 patients in the ACCORD EHR cohort. The SPRINT EHR cohort had a median age of
- 129 73 years (IQR, 61 to 84) and 2069 (52%) women), while the ACCORD EHR cohort had a
- 130 median age of 71 (IQR, 61 to 80) and 2032 (51%) women).
- 131

132 The Non-Conditioned SPRINT Digital Twin Cohort

133 We created 10 SPRINT-Twins (the non-conditioned SPRINT twin), which had a median age of

- 134 66 (IQR, 60 to 75) and 1516-1704 (32-38%) women (Table S1, S2). The SPRINT-Twin
- reproduced the distributions of the original variables (covariates, outcome, and time to outcome)
- in SPRINT as evidenced by an absolute standardized mean difference (ASMD) of less than 0.1
- 137 for each variable and a mean absolute standardized difference (MASMD) of 0.020 (SD 0.015)
- between the SPRINT Control (C) Arm and SPRINT-Twins C Arm and 0.021 (SD 0.014) between
- the SPRINT Intervention (I) Arm and SPRINT-Twins I Arm. In addition, all variables were
- 140 balanced between the I and C arms in the SPRINT-Twin, as evidenced by an ASMD of less than
- 141 0.1 for each variable and a MASMD of 0.011 (SD 0.016) between treatment arms across all
- 142 variables. This was similar to the MASMD between treatment arms of SPRINT, 0.021 (SD
- 143 0.018) and below the threshold where distributions are considered substantially dissimilar. The
- 144 correlations between variables were also preserved as evidenced by 88.4% concordance between
- 145 the Spearman correlations calculated between SPRINT's variables and those calculated between
- 146 the SPRINT twin's variables (Table S3, Figure S1).
- 147

148 The Conditioned SPRINT_{ACCORD} and ACCORD_{SPRINT} Digital Twin Cohorts

149 We then generated 10 SPRINT_{ACCORD} Twins, which were SPRINT twins conditioned with values

150 from the ACCORD cohort for 10 covariates, and 10 ACCORD_{SPRINT} Twins, which were

151	ACCORD twins conditioned with values from the SPRINT cohort for 10 covariates. The
152	SPRINT _{ACCORD} Twins had a median age of 62 years (IQR 58 to 68), 1106-1178 (46-49%) women
153	(Tables S4, S5) with mean 2345 (SD 25.9) or 49.5% in the C arm, 2388 (SD 24) or 50.5% in the
154	I arm. ACCORD _{SPRINT} Twins had a median age of 67 years (IQR 61 to 76), 1545-1677 (32-34%)
155	women with mean 4759 (SD 66) or 50.8% in the C arm and 4603 (SD 62) or 49.2% in the I arm
156	(Tables S6, S7). Across all treatment arm covariate distributions of the SPRINT _{ACCORD} Twins and
157	ACCORD _{SPRINT} Twins, there was little difference between the I and C arms, suggesting balanced
158	treatment arms as evidenced by each covariate having an ASMD between treatment arms of less
159	than 0.1 with an MASMD between treatment arms of 0.024 (SD 0.017) for SPRINT _{ACCORD}
160	Twins and 0.018 (SD 0.004) for ACCORD _{SPRINT} Twins, respectively (Figure 3a).
161	Comparing datasets, across all the conditioned covariates, the ASMD between the
162	SPRINT _{ACCORD} -Twin and ACCORD were less than 0.1, with a MASMD of 0.008 (SD 0.016),
163	and similarly, the ASMDs between ACCORD _{SPRINT} Twin and SPRINT were less than 0.1 with a
164	MASMD 0.023 (SD 0.014) compared to an MASMD of 0.46 (SD 0.20) for the same covariates
165	between SPRINT and ACCORD (Figure 3b). Out of the six non-conditioned covariates, white
166	race, systolic blood pressure, smoker, and LDL cholesterol level had ASMDs less than 0.1
167	between ACCORD vs. SPRINTACCORD Twin while systolic blood pressure, smoker, and angina
168	had ASMDs less than 0.1 between SPRINT and ACCORD _{SPRINT} Twin (Figure 3b). Conversely,
169	when conditioning on the opposite RCT and comparing datasets (ie. ACCORD vs
170	ACCORD _{SPRINT} Twin and SPRINT vs SPRINT _{ACCORD} Twin), the ASMD resembles ACCORD vs
171	SPRINT for the conditioned covariates (Figure S2). Similar to the non-conditioned twins, the
172	correlations between variables were also preserved, as evidenced by the 85.6% concordance of
173	the Spearman correlations between the ACCORD variables and the correlations between the

174	SPRINT _{ACCORD} Twin variables, the 78.4% concordance of correlations between the SPRINT
175	variables and the correlations between the SPRINT $_{ACCORD}$ Twin variables, the 84.5%
176	concordance of the correlations between the ACCORD variables and the $ACCORD_{SPRINT}$ twin
177	variables, and the 85.6% concordance of the correlations between the SPRINT variables and the
178	correlations between the ACCORD _{SPRINT} Twin variables (Table S3, Figure S1).
179	
180	Digital Twin Similarity Evaluation
181	Given the generated nature of the complementary covariates, each row of the conditioned twins
182	does not perfectly match the original cohort patients since it is updated with the conditioning
183	cohort data, so covariate distribution level assessments were conducted. When training a
184	multivariate logistic regression classifier to distinguish between RCT and twin data, in which an
185	accuracy of 0.5 is considered random chance, we found the median accuracy of the model to
186	correctly classify the data as real or fake to be 0.50 (IQR 0.49 to 0.51) for distinguishing
187	SPRINT from SPRINT Twins, 0.50 (IQR 0.49 to 0.51) for distinguishing SPRINT from
188	SPRINT _{ACCORD} Twins, 0.50 (IQR 0.49 to 0.55) for distinguishing ACCORD from ACCORD
189	Twins, and 0.50 (IQR 0.50 to 0.51) for distinguishing ACCORD from ACCORD _{SPRINT} Twins,
190	compatible with the SPRINT twins not being distinguishable from the original trial. When
191	assessing differentiation capability for each covariate by training and testing single variate
192	logistic regression models, the overall median accuracy was 0.50-0.51 across comparisons
193	(Figure S3).
194	

195 Sensitivity Analyses

models at various training sample sizes, batch sizes, and number of epochs of training. At a
training size of 1% and 25% of the SPRINT data, 81% of the models converged, while 94%
converged with 50% and 100% of the data. All models were balanced across the training sample
sizes. The proportion of models that reproduced the non-significant hazard ratio seen in
ACCORD increased with the training sample and was in a majority of the samples with a sample
size >10% of the trial (Table S8).
Comparison of RCT-Twin-GAN to other Synthesizer Models
Our method consistently scored among the best in all statistical comparisons and correlations
(Table S9, S10). It was superior to the other methods in machine learning efficacy, in which a
gradient boosting classifier trained on generated digital twin values predicted original RCT
gradient boosting classifier trained on generated digital twin values predicted original RCT values (Table S11).
gradient boosting classifier trained on generated digital twin values predicted original RCT values (Table S11).
gradient boosting classifier trained on generated digital twin values predicted original RCT values (Table S11). Estimating the Primary Composite Outcome in the Non-Conditioned Twins

ACCORD trials, which included a significant reduction in cardiovascular events in SPRINT's

intervention arm compared with control (hazard ratio 0.75 [0.64-0.89 95% CI, p<0.001]) without

a significant reduction in a similar primary composite outcome in ACCORD (hazard ratio 0.88

215 [0.73 to 1.06 95% CI, p=0.20]). In the SPRINT-Twin without conditioning, the median hazard

ratio across 10 generated SPRINT-Twin datasets was 0.73 (CI 0.61-0.87), with the 10

217 replications performed to ensure the reproducibility of the findings. This was comparable to the

218 HR of 0.75 in the SPRINT trial.¹³ Similarly, the ACCORD-Twin without conditioning replicated

- the primary results of the ACCORD trial, with a median HR of 0.89 (CI 0.79-1.0) comparable to
- 220 the HR of 0.88 of the ACCORD trial.¹⁴
- 221

222 Estimating the Primary Composite Outcome in the Conditioned Twins

- 223 We then demonstrated the ability of RCT-Twins to replicate the known treatment effects of a
- second population with the SPRINT_{ACCORD}-Twin the SPRINT-Twin that was conditioned on
- 225 ACCORD. We found the median hazard ratio of 10 SPRINT_{ACCORD}-Twin datasets was 0.87 (CI
- 226 0.68-1.13), this time comparable to the HR of 0.88 of the ACCORD trial (Figure 4a). In contrast,
- in 10 replicated digital twins of the ACCORD cohort conditioned on covariate distributions in
- 228 SPRINT (ACCORD_{SPRINT}-Twin), reproduced the significant effect size seen in SPRINT (HR

229 0.75) with a median hazard ratio of 0.79 (CI 0.72-0.86) (Figure 4b).

230

231 Estimating the Treatment Effect of SPRINT and ACCORD in the EHR

In a descriptive substudy, we demonstrated the ability to estimate SPRINT and ACCORD

primary composite outcomes in patient populations reflecting a large US health system, YNHHS.

- The same 10 covariates used to build conditioned SPRINT and ACCORD twins were
- 235 computably extracted from the YNHHS EHR by clinician experts to define covariates in the
- corresponding EHR cohorts and build digital twins of SPRINT and ACCORD conditioned on
- corresponding EHR cohorts (Tables S12-S15). In the digital twin of SPRINT conditioned on the
- 238 corresponding EHR cohort (SPRINT_{EHR}-Twin), we confirmed the replication of RCT features,
- including covariate balance across treatment arms (MASMD 0.03 (SD 0.03), (Figure S4). In this
- 240 SPRINT_{EHR}-Twin the median primary composite outcome HR was 0.84 (95% CI, 0.64-1.09)

across the 10 replications. Similarly, the ACCORD_{EHR}-Twin replicated both RCT features and
EHR covariate distributions, with a median primary composite outcome HR of 0.94 (CI 0.8-1.1).

243

244 **DISCUSSION**

245

246 We present RCT-Twin-GAN, a deep generative model that utilizes clinical knowledge of

covariate relationships to synthesize a digital twin of an RCT with selected covariate

248 distributions from a second population, such as another RCT cohort or a general patient

249 population reflected in an EHR. RCT-Twin-GAN created digital twins that replicate the

250 fundamental feature of RCTs, i.e., balanced covariates across treatment arms, but also reflected

the covariate distributions of this second population's distribution. In addition, the RCT-Twin-

252 GAN digital twin cohorts were indistinguishable from the SPRINT RCT cohorts, reproduced

253 RCT covariate correlations, and outperformed other model architectures. Moreover, in a positive

254 control experiment within a two-RCT system where treatment effects were known from well-

255 conducted experiments but were discordant across the RCTs, the RCT-Twins conditioned on

256 covariates from the opposing RCT replicated the results observed in the other RCT,

257 demonstrating the value of examining the effect of population characteristics on study outcomes.

258 We also demonstrate that the approach is flexible to these characteristics drawn from any

259 population, thereby enabling a quantitative evaluation of an RCT's potential treatment effects in

260 populations that differed from those included in the trial.

Our work has built upon the established need to quantify generalizability of RCTs to new populations.³² Prior methods, such as standardization of event rates, allow adjustment by single variables, which groups patients together by singular stratification.³³ Others have used distance metrics and decision tree machine learning techniques to represent the complex interplay of

covariates and characterize the heterogeneity of treatment effect.^{8–10,23,34–36} Prior generative 265 266 methods have used statistical machine learning to build digital twins of control patients in 267 neurological clinical trials and observational studies with accurate reproduction of patient 268 trajectory at the individual level.^{35–37} Our method complements these by building trial-level 269 digital twins of a conditioning cohort that draw from the multiple covariate distributions and 270 outcomes of an RCT population to generate equivalent covariates in the conditioning population 271 and estimate population-level treatment effects from the RCT intervention. CTAB-GAN+ has 272 been used to build an RCT control patient population, but our studies have demonstrated superiority with DATGAN in reproducing trial baseline characteristics.³⁸ In addition, compared 273 274 to other GAN conditioning methods, our architecture is the only method that can condition on 275 multiple continuous and categorical variables, allowing for multi-variate correlations of the 276 conditioning cohort to be preserved. Statistical methods to assess heterogeneous treatment effects 277 across populations have generally focused on equalizing baseline characteristics between 278 populations using propensity score matching, but this scores one variable at a time, thereby 279 ignoring multi-variable differences across patients, and does not consider effect modifiers.³⁹ 280 We incorporate the distributions of multiple mutual pre-randomization covariates 281 available across datasets to ensure representation across multivariate axes. In addition, we utilize

clinician expertise to identify connections between covariates and build digital twins modeling the complex interplay of effect modifiers and outcomes. The result is a data-driven generated outcome of the conditioning cohort based on the correlations between multiple covariates and within overlapping covariate distributions between the two patient populations. In Table 1, we discuss the minimum requirements to estimate treatment effects across two populations, including cohort requirements, randomization, intervention and outcome, and sample size.

288 A unique feature of our model incorporates both rigorous statistical methods and clinical 289 knowledge to build digital twins of RCTs with representative covariate balance and effect modifier information. The DAG structure weights clinically relevant relationships between 290 291 covariates and outcomes and removes spurious correlations that would otherwise be included in 292 the GAN. Of note, the choice of the covariates was governed by primary analysis focused on 293 shared covariates between SPRINT and ACCORD. In real-world translations, a different 294 covariate set shared between a development and target population can be selected. In addition, 295 the ability of the ciDATGAN architecture to condition on multiple continuous and categorical 296 values is unique compared to competing architectures. Our ability to reproduce treatment effect 297 estimates from the conditioning cohort by sampling its covariate distributions relies on the 298 inference of important correlations between covariates during GAN training and digital twin 299 generation. Although prior digital twin studies have focused on supplementing RCTs with synthetic patients for controls^{35–38} and reproducing progression within the same cohort, our study 300 301 builds upon these by estimating the treatment effect across different patient populations. 302 Measuring the hazard ratios of treatment effect outcomes as an evaluation metric provided 303 valuable insights into the fidelity of the synthetic dataset in simulating clinical trial outcomes and 304 treatment responses.

Methodologically, ACCORD represents a second RCT that experimentally tested the same intervention as SPRINT but in a different population. This is essential as the effect estimates in a conditioned twin otherwise have no gold standard comparison. We demonstrate that conditioning generates effect estimates replicated in the trial that experimentally tested the intervention but arrived at a different conclusion, suggesting the validity of the produced estimates. This is the key methodological outcome of our experiments.

311 Moreover, there are direct clinical implications for both hypertension management and 312 evidence generation via clinical trials. Our work demonstrates that the observed effect estimate 313 differences in SPRINT and ACCORD emerge because of the nature of populations enrolled in 314 these trials, and not because of diabetes status. There has been a lack of clarity about whether 315 these effects suggested some consideration about blood pressure and its effects on diabetes. But 316 we demonstrate that even in a trial like SPRINT, if the enrolled population had key features that 317 resemble those seen in ACCORD, the trial could have produced a potentially null result. 318 Similarly, had ACCORD enrolled patients that resembled SPRINT – based on features other than 319 diabetes, it could have been positive. While these observations represent data experiments, this 320 was recently observed in the ESPRIT trial, where patients with diabetes benefitted from intensive 321 blood pressure lowering.⁴⁰

322 This has implications for the interpretation of clinical trials as well. We acknowledge that 323 our work is a proof-of-concept, but we demonstrate that trials can be evaluated in populations 324 that differ from those enrolled on key features to address whether embedded heterogeneous 325 treatment effects and differences in these covariates affect how these results should be 326 interpreted. Moreover, these experiments can guide the need for populations ideally chosen for 327 additional trials. Health systems could determine the likely treatment effect of an intervention in 328 their patient population to better contextualize their patient outcomes with the intervention by 329 developing population-wide digital twins. This effort to use general real-world evidence to 330 establish the efficacy of interventions has major regulatory support from agencies such as the US 331 Food and Drug Administration.⁴¹

332 There are limitations to consider. First, RCT-Twin-GAN uses a select set of variables to333 build the digital twin. We chose a smaller set of covariates to maximize efficiency and showed

334 that even with this small number of representative variables, we can build a digital twin that 335 successfully replicates treatment effect estimates. Second, our model relies on outside input for 336 identifying correlations between covariates, but we believe this can be considered a strength that 337 clinical expertise can be imbued into the model to reduce the weight of spurious correlations 338 inherent in data. Third, this is a post-hoc analysis of RCTs, but we show the ability of digital 339 twins to mirror covariate characteristics and treatment effects found in SPRINT and ACCORD. 340 Fourth, we only applied RCT-Twin-GAN to the SPRINT - ACCORD pair because it was the only 341 paired trial testing the same intervention with different results available through a public domain, 342 the National Heart, Lung, and Blood Institute Biologic Specimen and Data Repository 343 Information Coordinating Center (BioLINCC). As the data are publicly available, further 344 research can build upon this example, and we further anticipate applying our model to other 345 examples.

346 Fifth, we could not study glycemic effects on the intervention because SPRINT did not 347 control hyperglycemia or include diabetic patients as seen in ACCORD. Despite this, we 348 demonstrate a positive treatment effect aligned with SPRINT among the ACCORD patients, who 349 had a full range of glycemic management differences as part of the original ACCORD trial, and 350 so do not find evidence to suggest glycemic management differences produced the null results 351 observed in ACCORD. Sixth, GANs are known to have challenges with achieving successful 352 convergence between the discriminator and generator, so we have adapted the most successful 353 advances in GAN development to optimize convergence. We chose an architecture that reduces 354 spurious correlations by introducing a DAG to define the correlation structure between variables, 355 stabilized training with the most appropriate learning rate and batch normalization layers, and 356 incorporated a loss function that eliminated the risk of vanishing gradients to ensure optimal

357 model performance. Seventh, modeling real-world patients in the EHR can be challenging since 358 the data represents a snapshot of patients who seek care, but we choose patients from a diverse 359 tertiary care system to maximize the breadth of the general population identified. In addition, the 360 EHR covariates had to be operationally defined by experts to be analogous to the criteria used in 361 RCT, but this is a descriptive study that shows different covariate distributions can be modeled. 362 Finally, the true effect estimates in the EHR populations are unknown, and those estimated by 363 RCT-Twin-GAN should not inform care but rather give an idea of discordance or concordance 364 with the original RCT population. 365 We have introduced a new application of GANs to build synthetic cohorts by creating an 366 RCT digital twin reflective of different patient populations, including similar RCTs and real-367 world patients found in the EHR. Our study demonstrates a way to evaluate the generalizability 368 of an RCT to the general population by embedding covariate distributions that are more 369 representative of real-world populations. This amplifies the effects for those more frequently 370 seen in clinical practice. Overall, our model contributes significantly to the evidence supporting 371 the development of an RCT digital twin that more consistently mirrors real-world populations, 372 thereby enhancing inference for real-world patients. 373

- 070
- 374 METHODS
- 375

376 Data Source and Patient Populations

377 SPRINT and ACCORD Cohorts

From 2010-2013, at 102 clinical sites across the United States, participants were recruited for the
SPRINT RCT who were at least 50 years old, had a systolic blood pressure between 130 and 180
mm Hg, and had increased cardiovascular event risk, including cardiovascular disease with the

381 exception of stroke, chronic kidney disease, Framingham 10 year cardiovascular risk score of

- 382 15% or greater, and advanced age over 75. Patients with prior stroke, diabetes mellitus, and a
- 383 recent heart failure exacerbation had been excluded from the study.
- From 2001 to 2005, at 77 clinical sites across the United States and Canada, participants
- were recruited for the ACCORD RCT who had type 2 diabetes mellitus, a glycated hemoglobin
- level of 7.5% or greater, and either age 40 or older with cardiovascular disease or age 55 or older
- 387 with risk factors for cardiovascular disease and anatomical evidence of longstanding
- 388 hypertension or diabetes such as albuminuria or left ventricular hypertrophy. Patients with a BMI
- 389 over 45, a creatinine over 1.5 mg/dL, or serious illness were excluded.
- 390 <u>EHR cohorts</u>
- 391 The two EHR cohorts were extracted from patients within the Yale New Haven Health System
- 392 (YNHHS) from 2013 to 2023. The study was reviewed by the Yale Institutional Review Board
- and deemed exempt as it uses retrospective data. We sampled 100,000 adult patients and then
- filtered the cohort to those with an ICD-10-CDM code for hypertension (Table S16). Out of these
- patients, we filtered for patients with an ICD-10-CDM code for type 2 diabetes mellitus (Table
- 396 S16). Patients with both hypertension and type 2 diabetes mellitus billing codes were considered
- for the ACCORD EHR cohort. The remaining hypertension patients who did not have type 2
- 398 diabetes mellitus billing codes were considered for the SPRINT EHR cohort. We excluded
- 399 patients who did not have values for continuous covariates and patients above the age of 110. We
- 400 then sampled 4000 patients each for the ACCORD EHR and SPRINT EHR cohorts with values
- 401 for all conditioned covariates. We further excluded patients who had continuous values out of
- 402 range of the training cohort of SPRINT or ACCORD (Table S17).
- 403

404 Development of RCT Digital Twins Conditioned on a Second Patient Population

- 405 We adapted CGAN models to create digital twin datasets of an RCT conditioned on covariate
- 406 distributions from a second patient population. We first built a SPRINT digital twin (SPRINT-
- 407 twin) trained on the SPRINT cohort without a second conditioning cohort. We then built a
- 408 SPRINT digital twin conditioned on the ACCORD participant population (SPRINT_{ACCORD}-Twin)
- 409 with the intention of reproducing the ACCORD primary composite outcome in a SPRINT digital
- 410 twin (Figure 1). To implement this, we applied the Conditional inputs for Direct Acyclic Tabular
- 411 Generative Adversarial Networks (CiDATGANs), a conditional tabular GAN that uses a directed
- 412 acyclic graph (DAG) to assign relationships between pre-randomized covariates.^{29,42} The DAG
- 413 ensures clinically relevant connections are introduced between covariates and prevents the
- 414 weighting of spurious correlations between covariates. To condition the digital twins on the other
- 415 RCT population, we mapped 33 equivalent covariates between SPRINT and ACCORD (Table

416 S18).

417

418 Covariate Extraction for SPRINT, ACCORD, and the EHR

419 In order to condition the SPRINT digital twin (SPRINT-Twin) on equivalent ACCORD

420 covariates (SPRINT_{ACCORD}-Twin), we mapped 33 equivalent covariates between the two cohorts,

- 421 which included demographics such as age, gender, race, and ethnicity, conditions and social
- 422 history, such as smoking history, family history of cardiovascular disease (CVD),
- 423 hyperlipidemia, left ventricular hypertrophy (LVH) and prior myocardial infarction (MI),
- 424 medications such as taking aspirin or statins, procedures such as coronary revascularization, and
- 425 laboratory values and vital signs such as glomerular filtration rate (GFR), glucose, and systolic
- 426 blood pressure (Table S18). We also included outcome, time to outcome, and treatment arm

427 assignment. We limited the maximum time to outcome to five years, censoring all subsequent428 outcomes.

429 To build the DAG, an expert clinician identified 16 representative variables of the 33 430 mapped between SPRINT and ACCORD to represent all clinical areas such as demographics, 431 conditions, medications, family history, symptoms, social history, procedures, vital signs, and 432 laboratory and EKG measures, and also maintaining a balance of both categorical and continuous 433 variables. All demographic variables were included since they are available for everyone in the 434 EHR cohort. The variables included continuous covariates of age at randomization, GFR, heart 435 rate, LDL cholesterol, and systolic blood pressure, and categorical covariates converted to a 436 binary assignment of the presence (1) or absence (0) of angina, Black race, BMI, current smoker, 437 family history of CVD, female sex, Hispanic ethnicity, LVH, previous MI, statin use, and White 438 race (Table S18). Since BMI was considered a binary variable in ACCORD (above or below 32 439 kg/m^2), we used a similar definition in SPRINT.

Variables related to exclusion criteria of at least one of the cohorts were not included in 440 441 the conditioning of the model or constructing the DAG because of the lack of overlap in the 442 distribution of these covariate values between the SPRINT and ACCORD cohorts. These 443 included glucose and diabetes mellitus. The DAG construction includes an iterative process of 444 expert assessment of clinically relevant pairs and the causal direction within the pairs and 445 calculation of correlations between unpaired variables (Table 2). The final DAG included 71 446 connections (Figure 2, Table S19). The arrows' direction pointed from the independent covariate 447 to the dependent covariate. No arrow pointed to the treatment arm covariate, labeled "Group", 448 since this assignment was independent of all covariates. All covariates and the "Group" pointed 449 to the "Outcome" and "Time to Outcome" covariates since all covariates and treatment arm

assignment were thought to influence the outcome (Figure 2, Table S19). We used the 10
covariates with the largest absolute standardized mean difference between SPRINT and
ACCORD as the conditioned covariates in order to condition from the covariate distributions
most representative of the second cohort. The included binary and continuous covariates, in the
order of increasing dissimilarity between cohorts, were black race, history of previous MI,
female sex, statin use, LVH, BMI, heart rate, age at randomization, family history of CVD, and
GFR.

457 Since we sought to condition on the EHR populations as well, we extracted the 10 458 conditioned covariates established in the prior analysis from the EHR as well (Table S16). Only 459 patients with a value for the demographics sex, race, and age (based on an available date of 460 birth), the vital signs BMI and heart rate, and the laboratory test eGFR (or computable from 461 serum creatinine), were included. The binary covariates of family history of CVD, LVH, 462 previous MI, and statin use were considered not present (assigned 0) if they were not recorded in 463 the patient's EHR, as is the norm for observational research studies in the EHR.⁴³ Age was 464 calculated on October 1, 2023 (EHR query date), unless they were deceased, where we used the 465 death date to define their last known age. We used this index date to consider most current 466 clinical characteristics of the patient to estimate their treatment effect, the equivalent of the 467 randomization to treatment arm date in the RCT.

468

469 Design of the RCT-Twin-GAN Model

470 RCT-Twin-GAN is a Generative Adversarial Network model, which is a deep learning model
471 rooted in game theory that pits a generator, the neural network that creates synthetic data, against
472 a discriminator, the neural network that distinguishes between the real data it is trained on and

473 the synthetic data created by the generator. The minimization of the discrimination between real 474 and synthetic data allows for the GAN to make realistic digital twins of the cohort on which it is developed.⁴⁴ The neural networks are comprised of Long Short Term Memory (LSTM) cells, 475 476 which are structured to retain information from prior inputs in addition to the current variable 477 input.⁴⁵ GANs have been adapted to accurately synthesize tabular data such as EHR data.^{27,28,46} 478 GANs can also integrate data from a second patient population through conditioning the model 479 on sample covariate values from the original cohort within the covariate distribution of the conditioning cohort, or the second patient population.^{28,29,46} To avoid the well-documented 480 481 challenges with consistently achieving convergence in GANs, our model utilizes Wasserstein loss to overcome training instability and prevent vanishing gradients.⁴⁷ 482 483 RCT-Twin-GAN is based on the architecture of CiDATGAN, which is an extension of 484 DATGAN with an additional feature of conditioning covariates with distributions from a second population.^{29,42} The DATGAN and CiDATGAN models employ a unique feature, allowing the 485 486 generator to have the relationships between covariates and outcomes of the original training 487 cohort to be explicitly encoded via a Directed Acyclic Graph (DAG). This prevents overfitting of 488 the discriminator by defining the correlation structure between variables. It constrains the 489 number of relevant associations, prioritizing key features for the model to learn. In contrast to 490 other conditional GAN architectures that infer variable relationships solely by correlation, the 491 addition of DAG to the training of the CiDATGAN generator incorporates directed relationships 492 between pairs of variables to eliminate spurious correlations between variables. Continuous 493 variables were winsorized based on the min-max values of the covariate in the training dataset 494 (Table S17) to remove outlier values below the 2.5% and 97.5% percentiles, and categorical

495 variables were encoded into one-hot vectors and then fed into the discriminator as part of the496 input.

497 During the training phase, the generator combines Gaussian noise and attention vectors of 498 the LSTM cells in the order of the DAG relationships and transforms the covariates from the 499 original cohort using a fully connected layer in order to refine relationships and dependencies 500 between the inputs. CiDATGAN creates a key modification to the DATGAN architecture in 501 which the transformed conditional covariate inputs are also fed to the generator. Because of this 502 modification, the DAG is also modified so that all conditional covariates are source nodes. The 503 generator then synthesizes complementary values of the remaining covariates of the original 504 dataset. The discriminator is then trained to differentiate between the original versus generated 505 values of the remaining covariates from the original dataset. The discriminator is then trained to 506 differentiate between the original versus generated values of the remaining covariates from the 507 original dataset (Figure 1a).

508 During the sampling phase, the generator receives Gaussian noise, the modified DAG, 509 and conditioned covariate values from the conditioning cohort and produces synthetic data 510 without transformation in order to directly reflect the learned distribution from training while 511 maintaining the integrity of the inputs from the conditioning cohort. Therefore, the final synthetic 512 dataset incorporates the conditioning cohort inputs and generates complementary values for the 513 remaining covariates missing from the conditioning cohort. The generator creates a cohort digital 514 twin by producing one row of data at a time for each patient within the conditioning cohort 515 (Figure 1b).

516 The CiDATGAN was then trained with the DAG and encoded dataset to generate the517 synthetic dataset. We performed a hyperparameter grid search with different batch sizes and

518 epochs to find the best parameters to generate synthetic data with similar outcomes to the

519 original dataset (Table S20).

520

521 Application of RCT-Twin-GAN in SPRINT, ACCORD, and the EHR

522 We first used RCT-Twin-GAN to build a SPRINT-Twin, which created a DAG based on the

523 SPRINT cohort, trained the DATGAN architecture on the SPRINT cohort, and ran the sampling

524 phase of the DATGAN pipeline ten times, resulting in ten distinct synthetic twins. We then built

525 a SPRINT_{ACCORD}-Twin, which again created a DAG from and trained on the SPRINT cohort but

526 was conditioned on the ACCORD cohort, utilizing the CiDATGAN architecture. This meant that

527 the DAG was modified to remove connections going to the conditioning covariates, and in the

528 sampling phase, Gaussian noise and the conditioned covariate distributions from the ACCORD

529 cohort were inputs for the generator in order to create the final synthetic dataset. We sampled this

530 process for 10 iterations to make 10 SPRINT_{ACCORD}-Twin datasets. We repeated this process to

531 create ACCORD_{SPRINT}-Twin datasets by replacing ACCORD to be the training cohort and

532 SPRINT to be the conditioning cohort.

533 We repeated this training and conditioning process using the EHR cohorts as well.

534 Specifically, we trained RCT-Twin-GAN on the SPRINT cohort, conditioned on the SPRINT-

535 EHR cohort, and sampled 10 times to create SPRINT_{EHR}-Twins. We similarly made

536 ACCORD_{EHR}-Twins with ACCORD and the ACCORD-EHR cohort.

537

538 Analysis of Cohort Representation in Digital Twins

539 To determine whether RCT-Twin-GAN created digital twins that are balanced by treatment arm,

540 we calculated the mean absolute standardized mean difference (MASMD) of all covariates of the

541	digital twins stratified by treatment arm assignment. A value of less than 0.1 was considered
542	adequate balance, consistent with convention when assessing the success of propensity score
543	matching. ⁴⁸ To assess the representation of the conditioning cohort in the synthetic digital twin,
544	we also calculated the absolute standardized mean difference (ASMD) between SPRINT and
545	ACCORD for each covariate, SPRINT-Twin and ACCORD, and SPRINT _{ACCORD} -Twin and
546	ACCORD. We also calculated the Spearman correlation between all variables for each RCT and
547	digital twin, discretized the correlations into 7 bins from -1 to 1, and then calculated the
548	proportion of covariate correlations from the RCT and twin data that were in the same bin
549	(termed correlation accuracy) and mean absolute difference between RCT covariate correlation
550	values and digital twin covariate correlation values as described in Li et al.27
551	
552	Evaluation of Digital Twin Similarity and Integrity
553	We evaluated whether any row of the digital twin cohorts matched the RCT patients by a
554	similarity score evaluation by Synthetic Data Vault. ⁴⁹ To assess distinguishability of the RCT
555	data from the conditioned twins, we trained and tested with a 70/30 split a multivariable logistic
556	regression classifier to differentiate between the RCT and digital twin, which has been used to
557	assess the integrity of prior digital twins. ³⁷
558	

559 Comparison of RCT-Twin-GAN to other synthesizer models

560 We compared the DATGAN architecture used in RCT-Twin-GAN to 5 competing models

- 561 including Conditional Tabular GAN (CTGAN)²⁸, Conditional Tabular GAN+ (CTABGAN+)⁵⁰,
- 562 CopulaGAN⁵¹, GaussianCopula⁵¹, and Triplet-based Variational Autoencoder (TVAE)²⁸. We
- 563 utilized the non-conditioned DATGAN architecture because none of the comparator models have

the flexibility to condition multiple continuous and categorical variables like the CiDATGAN architecture. Specifically, we tested the mean absolute error, R², root mean squared error, standardized root mean squared error, and Pearson correlation between the distribution of unique values in the RCT compared to the digital twin. We also tested machine learning efficacy, in which a gradient bosting classifier is trained on twin data and evaluated on how well it generates real data.

570

571 Estimation of Treatment Effect on Cardiovascular Outcomes in the Digital Twins

In order to assess the ability of RCT-Twin-GAN to estimate RCT treatment effect outcomes in
populations other than the original RCT, we calculated the hazard ratio of cardiovascular
outcomes stratified by treatment arms in each of the digital twin cohorts using cox proportional
hazard models. We utilized hazard ratios to evaluate the comparative risks of events over time
between different treatment groups within the synthetic data. This analytical approach allowed us
to gauge the effectiveness of the synthetic dataset in accurately representing the underlying
dynamics of treatment effects and event occurrences observed in real-world scenarios.

We reported the median hazard ratio and 95% confidence intervals for the 10 SPRINT-Twin, SPRINT_{ACCORD}-Twin, and ACCORD_{SPRINT}-Twin digital twins. In order to demonstrate the ability to estimate treatment effect outcomes in a variety of cohorts, we calculated the hazard ratio and 95% confidence intervals of cardiovascular outcomes of the SPRINT_{EHR}-Twins and ACCORD_{EHR}-Twins as well.

584

585 Statistical Analysis

586	Categorical variables were summarized as numbers with percentages, and continuous variables
587	were summarized as median with 25% and 75% interquartile ranges (IQR) or mean with
588	standard deviation (SD). Covariate distributions were compared using ASMD and standard
589	deviations and Spearman correlations between covariates and graphed as love plots comparing
590	datasets and heatmaps of the correlations. Data was winsorized at 2.5% and 97.5% percentiles to
591	remove outliers. Survival analysis was conducted using unadjusted cox proportional hazard
592	models with p values calculated after 5 years and presented as Kaplan Meier survival curves.
593	Hazard ratios across digital twins and SPRINT and ACCORD cohorts were presented as forest
594	plots with 95% confidence interval error bars. Analyses were conducted using python 3.9, with
595	packages specified in the supplement.
596	
597	DATA AVAILABILITY
597 598	DATA AVAILABILITY The SPRINT and ACCORD cohorts are publicly available through the National Heart, Lung, and
597 598 599	DATA AVAILABILITY The SPRINT and ACCORD cohorts are publicly available through the National Heart, Lung, and Blood Institute Biologic Specimen and Data Repository Information Coordinating Center
597 598 599 600	DATA AVAILABILITY The SPRINT and ACCORD cohorts are publicly available through the National Heart, Lung, and Blood Institute Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). The SPRINT dataset is available at https://biolincc.nhlbi.nih.gov/studies/sprint/
597 598 599 600 601	DATA AVAILABILITY The SPRINT and ACCORD cohorts are publicly available through the National Heart, Lung, and Blood Institute Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). The SPRINT dataset is available at <u>https://biolincc.nhlbi.nih.gov/studies/sprint/</u> and the ACCORD dataset is available at <u>https://biolincc.nhlbi.nih.gov/studies/accord/</u> . The Yale
597 598 599 600 601 602	DATA AVAILABILITY The SPRINT and ACCORD cohorts are publicly available through the National Heart, Lung, and Blood Institute Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). The SPRINT dataset is available at <u>https://biolincc.nhlbi.nih.gov/studies/sprint/</u> and the ACCORD dataset is available at <u>https://biolincc.nhlbi.nih.gov/studies/accord/</u> . The Yale electronic health record cohorts are not available due to the use of patient data.
597 598 599 600 601 602 603 604	DATA AVAILABILITY The SPRINT and ACCORD cohorts are publicly available through the National Heart, Lung, and Blood Institute Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). The SPRINT dataset is available at <u>https://biolincc.nhlbi.nih.gov/studies/sprint/</u> and the ACCORD dataset is available at <u>https://biolincc.nhlbi.nih.gov/studies/accord/</u> . The Yale electronic health record cohorts are not available due to the use of patient data. CODE AVAILABILITY
597 598 599 600 601 602 603 604 605	DATA AVAILABILITY The SPRINT and ACCORD cohorts are publicly available through the National Heart, Lung, and Blood Institute Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). The SPRINT dataset is available at https://biolincc.nhlbi.nih.gov/studies/sprint/ and the ACCORD dataset is available at https://biolincc.nhlbi.nih.gov/studies/sprint/ electronic health record cohorts are not available due to the use of patient data. CODE AVAILABILITY The code for reproducing the treatment effect estimates, digital twins, and analysis figures will
597 598 599 600 601 602 603 604 605 606	DATA AVAILABILITY The SPRINT and ACCORD cohorts are publicly available through the National Heart, Lung, and Blood Institute Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). The SPRINT dataset is available at https://biolincc.nhlbi.nih.gov/studies/sprint/ and the ACCORD dataset is available at https://biolincc.nhlbi.nih.gov/studies/sprint/ electronic health record cohorts are not available due to the use of patient data. CODE AVAILABILITY The code for reproducing the treatment effect estimates, digital twins, and analysis figures will be available during peer review in an accompanying file, and the code will be made publicly
597 598 599 600 601 602 603 604 605 606 607	DATA AVAILABILITY The SPRINT and ACCORD cohorts are publicly available through the National Heart, Lung, and Blood Institute Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). The SPRINT dataset is available at https://biolincc.nhlbi.nih.gov/studies/sprint/ and the ACCORD dataset is available at https://biolincc.nhlbi.nih.gov/studies/accord/. The Yale electronic health record cohorts are not available due to the use of patient data. CODE AVAILABILITY The code for reproducing the treatment effect estimates, digital twins, and analysis figures will be available during peer review in an accompanying file, and the code will be made publicly available upon publication.

608

610 **REFERENCES**

- 611 1. Averitt AJ, Ryan PB, Weng C, Perotte A. A conceptual framework for external validity. J
- 612 *Biomed Inform.* 2021;121:103870.
- 613 2. Rothwell PM. External validity of randomised controlled trials: "To whom do the results of
- 614 this trial apply?" *Lancet*. 2005;365:82–93.
- 615 3. Filbey L, Zhu JW, D'Angelo F, et al. Improving representativeness in trials: a call to action
- 616 from the Global Cardiovascular Clinical Trialists Forum. *Eur Heart J.* 2023;44:921–930.
- 617 4. Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the
- 618 representativeness of randomized controlled trial samples and implications for the external
- 619 validity of trial results. *Trials*. 2015;16:495.
- 620 5. Ranganathan M, Bhopal R. Exclusion and inclusion of nonwhite ethnic minority groups in 72
- 621 North American and European cardiovascular cohort studies. *PLoS Med.* 2006;3:e44.
- 622 6. Sardar MR, Badri M, Prince CT, Seltzer J, Kowey PR. Underrepresentation of women, elderly
- 623 patients, and racial minorities in the randomized trials used for cardiovascular guidelines. JAMA
- 624 Intern Med. 2014;174:1868–1870.
- 625 7. DeFilippis EM, Echols M, Adamson PB, et al. Improving Enrollment of Underrepresented
- 626 Racial and Ethnic Populations in Heart Failure Trials: A Call to Action From the Heart Failure
- 627 Collaboratory. *JAMA Cardiol*. 2022;7:540–548.

628	8. Oikonomou EK, Spatz ES, Suchard MA, Khera R. Individualising intensive systolic blood
629	pressure reduction in hypertension using computational trial phenomaps and machine learning: a
630	post-hoc analysis of randomised clinical trials. Lancet Digit Health. 2022;4:e796-e805.
631	9. Oikonomou EK, Suchard MA, McGuire DK, Khera R. Phenomapping-Derived Tool to
632	Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes. Diabetes

633 *Care*. 2022;45:965–974.

10. Oikonomou EK, Van Dijk D, Parise H, et al. A phenomapping-derived tool to personalize the

635 selection of anatomical vs. functional testing in evaluating chest pain (ASSIST). *Eur Heart J*.

636 2021;42:2536–2548.

637 11. Patel HC, Hayward C, Dungu JN, et al. Assessing the Eligibility Criteria in Phase III

638 Randomized Controlled Trials of Drug Therapy in Heart Failure With Preserved Ejection

639 Fraction: The Critical Play-Off Between a "Pure" Patient Phenotype and the Generalizability of

640 Trial Findings. *J Card Fail*. 2017;23:517–524.

12. Lim YMF, Molnar M, Vaartjes I, et al. Generalizability of randomized controlled trials in
heart failure with reduced ejection fraction. *Eur Heart J Qual Care Clin Outcomes*. 2022;8:761–
769.

13. SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A Randomized Trial of

645 Intensive versus Standard Blood-Pressure Control. *N Engl J Med.* 2015;373:2103–2116.

646 14. ACCORD Study Group, Cushman WC, Evans GW, et al. Effects of intensive blood-pressure
647 control in type 2 diabetes mellitus. *N Engl J Med*. 2010;362:1575–1585.

648	15. Carson JL	, Brooks MM.	, Hébert PC.	et al. Restrictive or]	Liberal	Transfusion	Strategy in
			/				

- 649 Myocardial Infarction and Anemia. *N Engl J Med.* 2023;389:2446–2456.
- 650 16. Ducrocq G, Gonzalez-Juanatey JR, Puymirat E, et al. Effect of a Restrictive vs Liberal Blood
- 651 Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial
- 652 Infarction and Anemia: The REALITY Randomized Clinical Trial. *JAMA*. 2021;325:552–560.
- 17. Joosten LPT, van Doorn S, van de Ven PM, et al. Safety of Switching from a Vitamin K
- Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial
- 655 Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial. *Circulation*. 2023.
- Published onlineAugust 27, 2023. https://doi.org/10.1161/CIRCULATIONAHA.123.066485.
- 657 18. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus Warfarin in Patients with
- 658 Atrial Fibrillation. *N Engl J Med*. 2011;365:981–992.
- 659 19. Jane-wit D, Horwitz RI, Concato J. Variation in results from randomized, controlled trials:
- stochastic or systematic? *J Clin Epidemiol*. 2010;63:56–63.
- 661 20. Krakoff LR. A tale of 3 trials: ACCORD, SPRINT, and SPS3. What happened? *Am J*662 *Hypertens*. 2016;29:1020–1023.
- 663 21. Chobanian AV. Hypertension in 2017-what is the right target? *JAMA*. 2017;317:579–580.
- 664 22. Huang C, Dhruva SS, Coppi AC, et al. Systolic blood pressure response in SPRINT (Systolic
- 665 Blood Pressure Intervention Trial) and ACCORD (Action to Control Cardiovascular Risk in
- 666 Diabetes): A possible explanation for discordant trial results. *J Am Heart Assoc.* 2017;6.

- 667 23. Laffin LJ, Besser SA, Alenghat FJ. A data-zone scoring system to assess the generalizability
- of clinical trial results to individual patients. *Eur J Prev Cardiol.* 2019;26:569–575.
- 669 24. Liu R, Rizzo S, Whipple S, et al. Evaluating eligibility criteria of oncology trials using real-
- 670 world data and AI. *Nature*. 2021;592:629–633.
- 671 25. Ge Q, Huang X, Fang S, et al. Conditional Generative Adversarial Networks for
- 672 Individualized Treatment Effect Estimation and Treatment Selection. *Front Genet*.
- **673** 2020;11:585804.
- 674 26. Yoon J, Jordon J, Van Der Schaar M. Ganite: Estimation of individualized treat- ment effects
- using generative adversarial nets. 2018. Accessed November 9, 2023.
- 676 https://openreview.net/pdf?id=ByKWUeWA-.
- 677 27. Li J, Cairns BJ, Li J, Zhu T. Generating synthetic mixed-type longitudinal electronic health
- 678 records for artificial intelligent applications. *NPJ Digit Med.* 2023;6:98.
- 679 28. Xu L, Skoularidou M, Cuesta-Infante A, Veeramachaneni K. Modeling Tabular data using
- 680 Conditional GAN. *arXiv* [*csLG*]. 2019.
- 29. Lederrey G, Hillel T, Bierlaire M. ciDATGAN: Conditional Inputs for Tabular GANs. *arXiv [csLG]*. 2022.
- 683 30. He Z, Tang X, Yang X, et al. Clinical Trial Generalizability Assessment in the Big Data Era:
- 684 A Review. *Clin Transl Sci.* 2020;13:675–684.
- 685 31. Tripepi G, Jager KJ, Dekker FW, Zoccali C. Stratification for confounding--part 2: direct and
- 686 indirect standardization. *Nephron Clin Pract*. 2010;116:c322-5.

687	32. Duan T, Rajpurkar P, Laird D, Ng AY, Basu S. Clinical Value of Predicting Individual
688	Treatment Effects for Intensive Blood Pressure Therapy. Circ Cardiovasc Qual Outcomes.
689	2019;12:e005010.

690 33. Brantner CL, Nguyen TQ, Tang T, Zhao C, Hong H, Stuart EA. Comparison of methods that

691 combine multiple randomized trials to estimate heterogeneous treatment effects. *Stat Med.* 2024.

692 Published onlineJanuary 25, 2024. https://doi.org/10.1002/sim.9955.

693 34. Raghavan S, Josey K, Bahn G, et al. Generalizability of heterogeneous treatment effects

based on causal forests applied to two randomized clinical trials of intensive glycemic control.

695 *Ann Epidemiol.* 2022;65:101–108.

696 35. Fisher CK, Smith AM, Walsh JR, Coalition Against Major Diseases, Abbott, Alliance for

697 Aging Research, Alzheimer's Association, Alzheimer's Foundation of America, AstraZeneca

698 Pharmaceuticals LP, Bristol-Myers Squibb Company, Critical Path Institute, CHDI Foundation,

699 Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Forest Research Institute, Genentech,

700 Inc., GlaxoSmithKline, Johnson & Johnson, National Health Council, Novartis Pharmaceuticals

701 Corporation, Parkinson's Action Network, Parkinson's Disease Foundation, Pfizer, Inc., sanofi-

aventis. Collaborating Organizations: Clinical Data Interchange Standards Consortium (CDISC),

703 Ephibian, Metrum Institute. Machine learning for comprehensive forecasting of Alzheimer's

704 Disease progression. *Sci Rep.* 2019;9:13622.

36. Walsh JR, Smith AM, Pouliot Y, Li-Bland D, Loukianov A, Fisher CK. Generating Digital

706 Twins with Multiple Sclerosis Using Probabilistic Neural Networks. *arXiv* [*statML*]. 2020.

707	37. Bertolini D.	Loukianov AD	Smith AM.	et al. Modeling	Disease Prog	ression in Mild
,	STI Dertonin Di					10001011 111 171110

- 708 Cognitive Impairment and Alzheimer's Disease with Digital Twins. *arXiv* [csLG]. 2020.
- 38. Eckardt J-N, Hahn W, Röllig C, et al. Mimicking clinical trials with synthetic acute myeloid
- 710 leukemia patients using generative artificial intelligence. *NPJ Digit Med.* 2024;7:76.
- 711 39. Degtiar I, Rose S. A Review of Generalizability and Transportability. *Annual Review of*
- 712 Statistics and Its Application. 2023;10:501–524.
- 40. Liu J, Li Y, Ge J, et al. Lowering systolic blood pressure to less than 120 mm Hg versus less
- than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous
- stroke: an open-label, blinded-outcome, randomised trial. *Lancet*. 2024;404:245–255.
- 716 41. Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and
- 717 Research (CBER) U.S. Food and Drug Administration. Framework for FDA's Real World
- 718 Evidence Program. US Food & Drug Administration. 2018. Accessed March 6, 2024.
- 719 https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence.
- 42. Lederrey G, Hillel T, Bierlaire M. DATGAN: Integrating expert knowledge into deep
- real learning for synthetic tabular data. *arXiv [csLG]*. 2022.
- 43. Khera R, Schuemie MJ, Lu Y, et al. Large-scale evidence generation and evaluation across a
- network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of
- multinational, real-world comparative cardiovascular effectiveness and safety studies. BMJ
- 725 *Open*. 2022;12:e057977.

- 44. Goodfellow IJ, Pouget-Abadie J, Mirza M, et al. Generative Adversarial Networks. *arXiv [statML]*. 2014.
- 45. Hochreiter S, Schmidhuber J. Long short-term memory. *Neural Comput.* 1997;9:1735–1780.
- 46. Zhao Z, Kunar A, Van der Scheer H, Birke R, Chen LY. CTAB-GAN: Effective Table Data
- 730 Synthesizing. *arXiv* [*csLG*]. 2021.
- 47. Arjovsky M, Chintala S, Bottou L. Wasserstein GAN. *arXiv* [*statML*]. 2017.
- 48. Normand ST, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary
- angiography following acute myocardial infarction in the elderly: a matched analysis using
- propensity scores. *J Clin Epidemiol*. 2001;54:387–398.
- 49. Patki N, Wedge R, Veeramachaneni K. The synthetic data vault. In: 2016 IEEE International

736 *Conference on Data Science and Advanced Analytics (DSAA).* IEEE, 2016.

- 50. Zhao Z, Kunar A, Birke R, Chen LY. CTAB-GAN+: Enhancing Tabular Data Synthesis. *arXiv [csLG]*. 2022.
- 73951. Kamthe S, Assefa S, Deisenroth M. Copula flows for synthetic data generation. *arXiv*
- 740 [*statML*]. 2021.
- 741

742 ACKNOWLEDGEMENTS

The study is supported by the National Heart, Lung, and Blood Institute of the National Institutes
of Health (R01HL167858). Dr. Thangaraj and Dr. Oikonomou are also supported by the National
Heart, Lung, and Blood Institute of the National Institutes of Health (5T32HL155000-03 and
1F32HL170592-01, respectively).

747

748 CONTRIBUTIONS

749 PMT and SVS contributed equally to the study. RK conceived the study and PMT, SVS, EKO,

and RK drafted a research plan. EKO and PMT accessed and processed the data. PMT and SVS

developed and analyzed the GAN model. PMT, SVS, EKO, and RK drafted the manuscript. All

authors provided feedback regarding the study design and manuscript. RK supervised the study,

753 procured funding, and is the guarantor.

754

755 COMPETING INTERESTS

756 The authors Dr. Thangaraj, Mr. Shankar, Dr. Oikonomou, and Dr. Khera are coinventors of a 757 provisional patent related to the current work (63/606,203). Dr. Oikonomou is a co-inventor of 758 the U.S. Patent Applications 63/508,315 63/177,117, a cofounder of Evidence2Health (with Dr. 759 Khera), and has previously served as a consultant to Caristo Diagnostics Ltd (outside the present 760 work). Dr. Nadkarni is a founder of Renalytix, Pensieve, and Verici and provides consultancy 761 services to AstraZeneca, Reata, Renalytix, Siemens Healthineer, and Variant Bio, and serves a 762 scientific advisory board member for Renalytix and Pensieve. He also has equity in Renalytix, 763 Pensieve, and Verici. Dr. Mortazavi reported receiving grants from the National Institute of 764 Biomedical Imaging and Bioengineering, National Heart, Lung, and Blood Institute, US Food

765	and Drug Administration	, and the US De	partment of Defense	Advanced Research Projects
	8)	1	J

- Agency outside the submitted work. In addition, B.J.M. has a pending patent on predictive
- 767 models using electronic health records (US20180315507A1). Dr. Khera is an Associate Editor of
- 768 JAMA. He receives support from the National Heart, Lung, and Blood Institute of the National
- 769 Institutes of Health (under awards R01HL167858 and K23HL153775) and the Doris Duke
- 770 Charitable Foundation (under award 2022060). He also receives research support, through Yale,
- from Bristol-Myers Squibb, Novo Nordisk, and BridgeBio. He is a coinventor of U.S. Pending
- 772 Patent Applications 63/562,335, 63/177,117, 63/428,569, 63/346,610, 63/484,426, 63/508,315,
- and 63/606,203. He is a co-founder of Ensight-AI, Inc. and Evidence2Health, health platforms to
- improve cardiovascular diagnosis and evidence-based cardiovascular care.

775

776

FIGURES 778



A Training



781

782 A. In the training phase, the original cohort (pink) is a randomized clinical trial (RCT), and variables across all clinical domains are extracted from the cohort. The directed acyclic graph 783 (DAG) includes clinician-defined relationships between original cohort covariates and is inputed 784 785 to the generator, along with RCT values of the non-conditioned variables. The generator then creates the conditioned variables, and the discriminator must differentiate from the original RCT 786 conditioned variables and the generator conditioned variables. Once the disciminator cannot 787 788 distinguish between the original and generated values, the training is complete. B. In the sampling phase, conditioned variables from the RCT cohort are mapped to a conditioning cohort 789 790 (blue), examples of which are another RCT or a patient cohort in the electronic health record 791 (EHR). The trained generator then takes the conditioned variables from the conditioning cohort and noise as input, and then generates non-conditioned variables. The final cohort-conditioned 792 793 RCT twin has conditioned covariate values from the conditioning cohort (blue) and generated 794 non-conditioned covariates based off the relationships and correlations between covariates (light 795 purple). Abbreviations: DAG: Directed Acyclic Graph, EHR: electronic health record, and RCT: Randomized Clinical Trial. 796



Figure 2: Directed acyclic graph of RCT-Twin-GAN.

800

- 801 Directed relationships between covariates (in blue), time to outcome and outcome (in orange),
- and treatment arm designation ("Group") in green. Abbreviations: BMI: Body Mass Index, CVD:
- 803 Cardiovascular disease, FH: Family History, GFR: Glomerular Filtration Rate, LVH: Left
- ventricular hypertrophy, LDL: low-density lipoprotein, MI: Myocardial infarction, SBP: SystolicBlood Pressure.

806

807



809 Figure 3: Absolute standardized mean difference (ASMD) of covariates between datasets.

810

(A) ASMD of covariates between treatment arms of RCTs and digital twins. Markers include 811 SPRINT (red circle), ACCORD_{SPRINT} Twin (orange square), SPRINT_{ACCORD}-Twin (blue 812 triangle), and ACCORD (purple diamond). The digital twin ASMDs are the mean of the 10 813 814 digital twin samples with standard deviation error bars. (B) ASMD of covariates between RCTs and digital twins. Red circle represents ASMD between ACCORD and SPRINT, green triangle 815 represents ASMD between ACCORD and SPRINT_{ACCORD}-Twins, and the blue square represents 816 817 the ASMD between SPRINT and ACCORD_{SPRINT} Twins. The digital twin ASMDs are the mean of the 10 digital twin samples with standard deviation error bars. The grey dotted line represents 818 an ASMD of 0.1, and the black dotted line separates non-conditioned and conditioned covariates. 819 820 The conditioning covariates included Age, Black, BMI, FH CVD, Female, GFR, Heart Rate, 821 LVH, MI, and On Statin. Abbreviations: ASMD: Absolute Standardized Mean Difference, BMI: 822 Body Mass Index, CVD: Cardiovascular disease, C: Control Arm, FH: Family History, eGFR: 823 Glomerular Filtration Rate, I: Intervention Arm, LDL: low-density lipoprotein, LVH: Left 824 ventricular hypertrophy, MI: Myocardial infarction, SBP: Systolic Blood Pressure.



Figure 4: Hazard ratios of intensive blood pressure lowering on cardiovascular outcomes.



831 interval, the red diamond is the SPRINT hazard ratio and 95% confidence interval, and the grey

- dotted line represents a hazard ratio of 1. In (A), orange squares are the hazard ratio of major
- 833 cardiovascular outcome predicted for each twin run of ACCORD-conditioned SPRINT twins
- 834 with 95% confidence intervals and in (B) the blue triangles are SPRINT-conditioned ACCORD
- twins. Abbreviations: MACE: Major Cardiovascular Outcomes, SPRINT_{ACCORD}-Twin:
- 836 ACCORD-conditioned SPRINT Twin, ACCORD_{SPRINT}-Twin: SPRINT-conditioned ACCORD
- 837 twin.



Figure 5: Representative Kaplan-Meier curves of digital twins conditioned on EHR data.



(A) Kaplan-Meier curves of SPRINT treatment arms along with EHR-conditioned SPRINT 843 844 treatment arms, (B) Kaplan Meier curves of ACCORD treatment arms along with EHR-

- conditioned ACCORD treatment arm balance of the original cohorts and digital twins. 845
- Abbreviations: ACCORD_{EHR}Twin: ACCORD conditioned on EHR digital twin., C. Control arm, 846
- 847 EHR: Electronic Health Record, I: Intervention Arm, SPRINT_{EHR}-Twin: SPRINT conditioned on EHR digital twin. 848

850 TABLES

852

853

851 Table 1: Minimal Requirements for RCT-Twin-GAN

Rules	
1.	The model requires at least a pair of cohorts, one should be an RCT, the second should have the same covariates accessible and overlapping covariate distributions. This is, however, extendable to any number of cohorts.
2.	There must be at least two treatment arms in the RCT with any ratio of randomization.
3.	A measured outcome, categorical or continuous, should be available in the RCT to estimate treatment effect.
4.	A sample size of at least 100 is needed for model convergence, but at least 1000 participants and further hyperparameter tuning of the model is needed to accurately estimate treatment effects.

854 Table 2: Construction of the Directed Acyclic Graph

- 1. Assemble covariates, treatment arms, time to outcome, and outcome.
- 2. Assign treatment arm as a source node that only connects to time to outcome and outcome.
- 3. Ensure all covariates are connected to time to outcome and outcome.
- 4. Clinicians assess which covariates influence each other based off clinical knowledge, such as systolic blood pressure to left ventricular hypertrophy or current smoker to angina or MI.
- 5. Pearson and Spearman correlations are calculated between every unconnected pair of variables and those with both Pearson and Spearman correlations >0.75 are assessed.
- 6. Clinicians assess which of the suggested pairs are clinically relevant and add them to the DAG.
- 7. Repeat steps 5 and 6 until no more clinically relevant pairs are suggested.

855 856

Table 3: CiDATGAN Architecture, Training and Sampling

858

1. **DAG Construction:** For each cohort (e.g., SPRINT and ACCORD), we constructed a DAG representing the causal relationships between covariates and outcomes. This DAG was used to inform the generator about the relevant correlation structure and prevent overfitting of correlations from noise.

The graph G for a DAG is specified by the modeler to define the correlations between the variables in the data.

- Each variable V_t in the table T must be associated with a node in the graph G.
- A directed edge between two nodes, i.e. $V_{t1} \rightarrow V_{t2}$, means that the generation of the first variable V_{t1} will influence the generation of the second variable V_{t2} .
- The absence of a link between two variables means that their correlation is not directly learned by the Generator.

Once the DAG G was created, we defined several sets:

- $A(V_t)$: the set of ancestors of the variable V_t
- $D(V_t)$: the set of direct ancestors of the variable V_t
- $S(V_t)$: the set of source nodes leading to the variable V_t
- E(V_t): the set of in-edges of the variable V_t

2. **Training and Conditioning Phase:** The DATGAN architecture was trained on the original cohort data (e.g., SPRINT). Continuous and categorical variables from the dataset were encoded at the discriminator input. We introduced conditioning covariates to condition the generation of synthetic data. The DAG was constructed so that the conditioning covariates were removed and treated as source nodes because the discriminator was only trained on non-conditioned covariates. The generator utilized Gaussian noise, the DAG-informed covariate relationships, and the conditioned covariate values from the conditioning cohort to generate synthetic data. The discriminator was trained to distinguish between the generated synthetic data and the real cohort data.

The mathematical representations of these are included below:

 T_0 : Original cohort with N_0 variables (v_i^0 for $i - 1, ..., N_0$)

 T_C : Original cohort with N_C variables (v_i^C for $i - 1, ..., N_C$) where $N_O > N_C$

 N_{CV} : Number of common variables across both cohorts such that $N_{CV} \leq N_0$

These common variables are denoted as T_0^{ci} and T_c^{ci} for the original and conditioning cohorts respectively.

Goal: To generate complementary variables $T_0^{c} = T_0 - T_0^{ci}$ using the values of common variables T_c^{ci} as inputs.

Generator:

Let, G = Generator z = Gaussian Noise

 T_{C}^{ci} = Conditional Inputs Generates each variable in T_{O}^{c} Let $T_{O \rightarrow C}^{c,synth}$ = Generated Data

Discriminator:

Let,

D = Discriminator

D distinguishes between the real data T_0^{c} and generated data $T_{0\to C}^{c,synth}$

The model is trained on T_0 with the associated DAG structure where the conditional variables are source nodes.

The generation of synthetic variables V_t^0 in T_0^c using LSTM cells follows an order provided by the linearization of the DAG.

LSTM Cells:

Each LSTM cell LSTM_t is associated with the variable v_t^0 , ordered based on the DAG. The cell takes as input the cell state of the previous variable in the DAG C_{t-1} and the input tensor i_t , which is a concatenation of:

$$i_t = [z_t, f_{t-1}, a_t]$$

Where:

- z_t is a tensor of Gaussian noise.
- f_{t-1} is the transformed output of the previous LSTM cell in the DAG.
- a_t is the attention vector used to retain information from previous ancestors not directly linked to the current cell in the DAG.

Attention Vector a_t:

$$a_{t} = \sum_{k \in A9t) \setminus P(t)} \frac{\exp\left(\alpha_{k}^{t}\right)}{\sum_{j=1}^{|A(t)|} \exp\left(\alpha_{j}^{t}\right)} f_{k}$$

where $A(t)\P(t)$ is the set of ancestors of the variable v_t^C in the DAG, excluding direct predecessors, α^t is a learned attention weight vector, and f_k is the final output of the LSTM cell LSTM_k.

Output of LSTM Cells:

Each LSTM cell outputs two tensors, the new cell state C_t and the output of the cell h_t . This output is then passed through fully connected layers to get the synthetic values $v_t^{C,synth}$:

$$v_t^{O,synth} = FC(h_t)$$

The synthetic tensor is resized to a common size between all variables using an input transformer.

Handling Conditional Inputs:

For variables in T_0^{ci} , the generator needs the transformed output f_{t-1} of the direct ancestor and the direct output h_k of all ancestors.

Transformed Output f_t : The same type of input transformer is used to get f_t for the conditional inputs.

Dense (Fully connected) Layer Transformation:

Since LSTM output h_t is not available for conditional inputs, the original value v_t is transformed using a Dense layer:

 $h_t = Dense(v_t)$

The parameters in this Dense layer are learned during the training process, allowing the model to use the conditional inputs in the attention vector.

3. Sampling Process:

During the sampling phase, the model received Gaussian noise, the DAG, and the values of conditioned covariates for the patient, which can come from either the original dataset T_0^{ci} or the conditioning dataset T_C^{ci} . This combination was used to generate the final digital twin $(T_{0 \rightarrow C}^{c,synth})$ from each patient of the conditioning cohort, which included a copy of conditioned covariate values, and generated non-conditioned covariates based off the correlations between the covariates from the original cohort.

4. Sampling and Iterations:

Digital twin generation was repeated for a specified number of iterations (e.g., 10 iterations). In each iteration, the generator produced a synthetic dataset based on the conditioned covariates and Gaussian noise. Each iteration generated a complete digital twin cohort."